期刊文献+

英夫利西单抗对哮喘模型豚鼠抗肿瘤坏死因子-α的影响 被引量:2

Effect of Infliximab on TNF-α of guinea pigs asthma model
原文传递
导出
摘要 目的探讨英夫利西单抗对哮喘模型豚鼠抗肿瘤坏死因子-α(TNF-α)的影响。方法豚鼠50只,雌雄各半,随机分为5组:对照组,模型组,英夫利西单抗低、中、高剂量(5、10、15mg/kg)组,每组10只。模型组和英夫利西单抗各剂量组ip给予10%卵蛋白以致敏,对照组给予等量生理盐水;模型组和英夫利西单抗各剂量组再分两次给予2%卵蛋白溶液雾化吸入,对照组以等量生理盐水替代。每次激发前英夫利西单抗各剂量组ip相应剂量的英夫利西单抗,第二次激发后24h处死动物,对比各组血清、组织匀浆和肺泡灌洗液中TNF-α水平。结果模型组血清、组织匀浆、肺泡灌洗液中TNF-α浓度高于对照组(P<0.05),而英夫利西单抗各剂量组血清、组织匀浆、肺泡灌洗液中TNF-α的浓度低于模型组(P<0.05)。结论TNF-α与豚鼠哮喘形成密切相关;使用英夫利西单抗可以减少豚鼠哮喘模型血清、组织匀浆、肺泡灌洗液中TNF-α的产生。 Objective To investigate the effect of Infliximab on TNF-α of guinea pigs asthma model.Methods Guinea pigs(50),half male and female,were randomly divided into five groups,control,model,low-,mid-,and high-dose Infliximab(5,10,and 15 mg/kg)groups(n=10).Model and the Infliximab groups were ip administered with 10% ovalbumin to sensitivate,and the control group was given physiological saline.Model and Infliximab groups were atomizing inhalated twice with 2% ovalbumin solution,and the control group was given the same dose physiological saline.Infliximab groups were ip administered with appropriate doses of Infliximab before excitation each time,and animals were killed 24 h after the second excitation.TNF-α was detected in serum,tissue,and bronchoalveolar lavage fluid.Results TNF-α concentration in the serum,tissue homogenates,and bronchoalveolar lavage fluid in the model group was higher than that in the control group(P &lt; 0.05).However,TNF-α concentration in the serum,tissue homogenates,and bronchoalveolar lavage fluid of the Infliximab group was lower than that in the model group(P &lt;0.05).Conclusion TNF-α is related to the formation of the guinea pig asthma,and Infliximab could reduce TNF-α of serum,tissue homogenates,and bronchoalveolar lavage fluid in guinea pig model of asthma.
出处 《现代药物与临床》 CAS 2013年第3期308-311,共4页 Drugs & Clinic
关键词 英夫利西单抗 肿瘤坏死因子-Α 哮喘 气道炎症 Infliximab TNF-α asthma airway inflammation
  • 相关文献

参考文献11

二级参考文献139

共引文献11891

同被引文献46

  • 1陈业民,黄文杰,李胜利,梁坤.重症肺炎大鼠干扰素-γ、白细胞介素-6和肿瘤坏死因子-α含量变化[J].中国病理生理杂志,2007,23(3):492-494. 被引量:34
  • 2Colsman A, Carrascosa J M, Ferrandiz C, et al. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab [J]. J Eur Acad Dermatol Venereol, 2008, 22(9): 1131-1134.
  • 3Kagami S, Rizzo H L, Lee J J, et al. Circulating Thl7, Th22 and Thl cells are increased in psoriasis [J]. Jlnvest Dermatol, 2010, 130(5): 1373-1383.
  • 4Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randornizedcontrolled trial [J]. J Clin Immunol, 2009, 29(2): 210-214.
  • 5Antiga E, Volpi W, Chiarini C, et al. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris [J]. lnt J lmmunopathol Pharmacol, 2010, 23(3): 767-774.
  • 6Zaba L C, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Thl7 responses [J]. J Exp Med, 2007, 204(13): 3183-3194.
  • 7Brown S L, Greene M H, Gershon S K, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration [J]. Arthritis Rheum, 2002, 46(12): 3151-3158.
  • 8Antoni C, Krueger G C, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J]. Ann Rheum Dis, 2005, 64(8): 1150-1157.
  • 9Menter A, Feldman S R, Weinstein G D, et al. A randomized comparisonof continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis [J]. J Am AcadDermatol, 2007, 56(1): 31.
  • 10Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre [J]. Br J Dermatol, 2010, 162(5): 1117-1123.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部